Anakinra for the treatment of acute severe gout in critically ill patients

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 1, 2015, Pages 81-85

  Thueringer, Jessica T ^a,b   Doll, Natalie K ^a,b   Gertner, Elie ^a,b  

^a REGIONS HOSPITAL   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Acute gouty arthritis; Anakinra; Critically ill; Gout; IL 1 inhibition; Intensive care unit

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BURN; CLINICAL ARTICLE; COMORBIDITY; CRITICALLY ILL PATIENT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GOUT; HEMOPHAGOCYTIC SYNDROME; HERPES ZOSTER; HUMAN; INTENSIVE CARE; KIDNEY FAILURE; LEUKOPENIA; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; UNITED STATES; ARTHRITIS, GOUTY; CRITICAL ILLNESS; INTENSIVE CARE UNIT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; ARTHRITIS, GOUTY; CRITICAL ILLNESS; FEMALE; GOUT; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84937738597     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.02.006     Document Type: Article

References (11)

1. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
2. Jacques C., Gosset M., Berenbaum F., Gabay C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm 2006, 74:371-403.
3. Ghosh P., Cho M., Rawat G., Simkin P.A., Gardner G.C. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res 2013, 65:1381-1384.
4. Chen K., Fields T., Mancuso C.A., Bass A.R., Vasanth L. Anakinra[U+05F3]s efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010, 40:210-214.
5. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
6. Ottaviani S., Molto A., Ea H.K., Neveu S., Gill G., Brunier L., et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther 2013, 15:R123.
7. Anakinra-package insert. Stockholm (Sweden): Swedish Orphan Biovitrum AB; 2013.
8. Schlesinger N., Alten R.E., Bardin T., Schumacher H.R., Bloch M., Gimona A., et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomized, multicenter, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012, 71:1839-1848.
9. Schlesinger N., Mysler E., Lin H., De Meulemeester M., Rovensky J., Arulmani U., et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011, 70:1264-1271.
10. Schumacher H.R., Evans R.R., Saag K.G., Clower J., Jennings W., Weinstein S.P., et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res 2012, 64:1462-1470.
11. Yang B.B., Baughman S., Sullivan J.T. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003, 74:85-94.